Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
about
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineSimple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two LargeNew Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current TherapiesEfficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseHepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional studyHCV management in resource-constrained countries.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.Hepatitis C virus genotype 4: Genotype 1's little brother.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.Treatment Options in Hepatitis C.Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis CExpert opinion on the management of hepatitis C infection in Kuwait2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q28076883-58495459-8865-4267-9BBE-49CAEA19E380Q31121312-03940BD9-D184-4CC4-A50B-170B6883F210Q33560181-825334DD-53E6-42BA-8F63-1E89DB88297CQ33585021-9C69E9EF-6B6F-4828-B7CE-65B97C821C27Q36240269-B1C08312-B9C2-4F11-8945-8592E87B96DBQ37356018-67E2CA3A-C0FC-44AC-B04F-1D60CEA102CCQ38372939-2403428B-71E6-4CAB-87C6-4FC731D71357Q38893244-328B7503-A42D-4A31-9A9B-F4F3499C34F4Q39013086-A5520290-CB87-4D66-915C-9A0E4A046A5BQ39025320-ECD3C57E-0AA3-4878-830E-E49751B37638Q39104215-8713079B-08CF-4DD9-8923-4DFE93270324Q39112237-1C93D4A9-7C2C-4632-AE7D-26AC6468CE49Q41923068-E1C6BA75-1F49-46C5-8469-65104D5B6F6DQ46257659-2DE18AD7-932B-427E-8155-4D8F57A7CCF8Q47548361-79017AC9-5815-46C2-B28C-731770D45CCEQ54223871-7B1A4A2E-4438-4A51-8706-78A34EA06DD2Q54943151-285B0008-CE21-49C2-B13D-3306F24935A4Q56395991-4C2A94A6-FA60-4F1B-8CE1-62A6B8DFE741Q57490314-63F9ED5E-65BA-40A0-8F72-A297D29D5FF2Q58788714-0DE87D18-A0BA-496A-84ED-A891A4A798B8
P2860
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.
@en
type
label
Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.
@en
prefLabel
Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.
@en
P2093
P2860
P50
P356
P1433
P1476
Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.
@en
P2093
Armand Abergel
Deyuan Jiang
Evguenia Svarovskaia
Kathryn Kersey
Phillip S Pang
Sophie Metivier
Steven J Knox
Tarik Asselah
Veronique Loustaud-Ratti
P2860
P304
P356
10.1002/HEP.28706
P407
P577
2016-06-28T00:00:00Z